Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...

A new Cochrane review confirms that antidepressants effectively reduce symptoms of generalized anxiety disorder (GAD) under trial conditions, although there is limited data on long-term usage.

AI-driven tools harness ML algorithms to provide insights into anxiety disorders. Supervised ML models, such as logistic ...

MindMed has dosed the first subject in the Phase III Panorama study of MM120 ODT for the treatment of generalised anxiety ...

Have you ever felt a sinking feeling in your stomach that won’t go away, or woken up with heart palpitations and spent the rest of the day trying to overcome them?

The MM120 ODT Phase 3 clinical development program includes the Voyage and Panaroma studies in generalized anxiety disorder (GAD) and the Emerge study in major depressive disorder (MDD).

Antidepressants, such as Prozac, are already used to treat the condition but Canadian and Italian scientists set out to ...

Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.

A new Cochrane review confirms that antidepressants effectively reduce symptoms of generalized anxiety disorder (GAD) under ...

“Hyperthyroidism is often linked to Graves’ disease, another autoimmune condition that overstimulates the thyroid. Thyroid ...

A Cochrane review has concluded that antidepressants are more effective than placebo in reducing the symptoms of generalised anxiety disorder (GAD) in the short term.1 The National Institute for ...

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Mind Medicine (MNMD – Research Report). The associated price ...